International: Buyer announced for Nestle’s divested infant-nutrition licenses
Just days after it was announced that Nestle SA would agree to find a buyer for its licenses of infant formula as part of a deal to acquire Pfizer Inc., Aspen Pharmacare Holdings Ltd., based in South Africa, has struck a deal to buy the licenses that will allow the company to sell infant formula in Australia, South Africa and Namibia. Antitrust regulators in Australia have reportedly approved of the deal, while those in South Africa and Namibia are pending approval, according to Aspen. Aspen is the largest generic medicine producer in the Southern Hemisphere, supplying medicine to more than 150 countries. The move is part of a larger effort to expand businesses within Australia, Latin America and sub-Sahara Africa.
Full Content: Live Mint
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI